




The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 163% points. The greatest weakness of Crescent Biopharma INC is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 390%, being 138% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	127,220
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,175
Liabilities, Non-Current	0
Other Assets	257
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	707
Other Net Income	651
Other Revenues	0
Property and Equipment	1,107
Research and Development	24,100
Selling, General and Administrative Expense	9,832

Output Variable	Value in 1000 USD
Assets	128,583
Liabilities	8,882
Expenses	33,932
Revenues	0
Stockholders Equity	119,701
Net Income	-33,281
Comprehensive Net Income	-33,281
BaseVar	86,024
ECR before Limited Liability	331%
Economic Capital Ratio	390%